Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

China · Delayed Price · Currency is CNY

15.72

+1.83 (13.17%)

Jun 18, 2026, 3:00 PM CST

-6.86% (1Y)

Market Cap	8.13B -6.6%
Revenue (ttm)	1.41B +3.8%
Net Income	-14.34M
EPS	-0.03
Shares Out	516.99M
PE Ratio	n/a
Forward PE	76.16
Dividend	0.38 (2.45%)
Ex-Dividend Date	Jun 3, 2026

Volume	10,815,461
Open	13.86
Previous Close	13.89
Day's Range	13.81 - 15.74
52-Week Range	12.89 - 20.59
Beta	0.70
Analysts	Buy
Price Target	19.59 (+24.62%)
Earnings Date	Aug 28, 2026

About Nanjing Vazyme Biotech

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 3,002

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688105

Full Company Profile

Financial Performance

In 2025, Nanjing Vazyme Biotech's revenue was 1.38 billion, a decrease of -0.00% compared to the previous year's 1.38 billion. Losses were -16.61 million, -8.18% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 688105 stock is "Buy." The 12-month stock price target is ¥19.59, which is an increase of 24.62% from the latest price.

Price Target

¥19.59

(24.62% upside)

Analyst Consensus: Buy

Stock Forecasts